Top Page
Imugene Limited
(Sydney:IMU)
Imugene Limited (IMU) vs. S&P 500 (SPY)
Imugene Limited Business Overview & Revenue Model
Imugene Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.81M | 11.78M | 12.97M | 7.23M | 4.13M | Gross Profit |
| 4.97M | 9.57M | 10.56M | 5.27M | 4.05M | EBIT |
| -140.93M | -51.29M | -50.67M | -25.67M | -14.88M | EBITDA |
| -147.98M | -47.43M | -48.06M | -23.72M | -14.55M | Net Income Common Stockholders |
| -149.68M | -37.91M | -37.87M | -18.46M | -10.51M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 94.54M | 153.15M | 99.89M | 29.49M | 30.11M | Total Assets |
| 151.40M | 197.06M | 147.61M | 71.81M | 65.20M | Total Debt |
| 1.55M | 553.47K | 673.43K | 271.03K | 69.34K | Net Debt |
| -91.56M | -152.60M | -99.21M | -29.22M | -30.04M | Total Liabilities |
| 33.14M | 7.44M | 8.90M | 6.79M | 5.40M | Stockholders Equity |
| 118.25M | 189.63M | 138.70M | 65.02M | 59.81M |
| Cash Flow | Free Cash Flow | |||
| -106.78M | -29.78M | -30.93M | -18.58M | -11.62M | Operating Cash Flow |
| -101.73M | -29.78M | -30.67M | -13.13M | -10.13M | Investing Cash Flow |
| -7.25M | 9.63K | -414.16K | -5.48M | -1.52M | Financing Cash Flow |
| 49.43M | 82.98M | 101.35M | 17.99M | 22.71M |
Imugene Limited Technical Analysis
Imugene Limited Peers Comparison
Imugene Limited Corporate Events
Imugene Limited addressed shareholder concerns regarding its declining share price, attributing it to slow progress in its CF33 and OnCARlytics programs, market perceptions of high cash burn, and an increased short position. The company acknowledged the challenges of securing licensing deals, particularly for HER-Vaxx, and emphasized its ongoing efforts in business development. Imugene also explained its frequent capital raising as a necessity due to the high costs associated with running multiple technology platforms and clinical trials, which is a common scenario for biotech firms in the clinical development stage.
Imugene Limited has announced the application for quotation of 1,630,230 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s ongoing efforts to enhance its financial flexibility and support its strategic initiatives in the biotechnology sector, potentially impacting its market positioning and stakeholder interests.
Imugene Limited announced the cessation of a total of 3,439,132 restricted stock units due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perception regarding the company’s operational progress and strategic direction.
Imugene Limited has announced the issuance of 1,630,230 restricted stock units under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize and retain key personnel, potentially enhancing its operational capabilities and aligning employee interests with long-term company performance.
Imugene Limited has announced a webinar for shareholders and investors to discuss the latest business updates and answer frequently asked questions. This event, hosted by key executives, underscores the company’s commitment to transparency and engagement with stakeholders, potentially strengthening its industry position and stakeholder relations.
Imugene Limited has announced the clearance of the first dose level in the intravenous combination arm of its Phase 1 onCARlytics trial, known as OASIS, which targets adult patients with advanced or metastatic solid tumors. The trial aims to make solid tumors express the CD19 target, allowing them to be treated with approved CD19 targeting therapies. The trial is being conducted at multiple sites in the U.S., with plans to recruit 40-50 patients. This advancement in the trial marks a significant step in evaluating the safety and efficacy of onCARlytics, potentially impacting the treatment of solid cancers by providing a target for CD19 therapies.
Imugene Limited has announced that its allogeneic CAR T-cell therapy, azer-cel, has been granted Fast Track Designation by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This designation is expected to accelerate the development and review process, potentially improving patient access to this promising therapy. Azer-cel, which uses pre-manufactured donor T-cells, aims to overcome challenges associated with autologous CAR T therapies, such as manufacturing delays and limited patient access. Clinical trials have shown promising results, with a manageable safety profile and no instances of immune effector cell-associated neurotoxicity syndrome. This development positions Imugene as a key player in addressing critical unmet needs in the treatment of aggressive non-Hodgkin’s lymphoma.
Imugene Limited has announced the quotation of 2,234,375 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to strengthen its financial position and support its ongoing research and development efforts in cancer immunotherapy, potentially impacting its market presence and stakeholder interests.
Imugene Limited has appointed Darren Keamy as its new Chief Financial Officer and Company Secretary. Keamy, with over 25 years of experience in corporate finance within the biopharmaceutical industry, previously played a crucial role in the growth of Clinuvel Pharmaceuticals. His expertise in financial strategy and international expansion is expected to support Imugene’s strategic growth and the advancement of its immuno-oncology pipeline.
Imugene Limited has been granted a patent in India for its CF33 oncolytic virotherapy technology, extending its intellectual property protection globally. This patent, which lasts until 2037, strengthens Imugene’s position in key markets like the US and Japan, and underscores its commitment to advancing its oncolytic virotherapy pipeline. The CF33 technology, developed by Professor Yuman Fong, targets and destroys cancer cells while stimulating the immune system, potentially improving patient outcomes. This development is a significant step in Imugene’s mission to deliver next-generation immunotherapies worldwide.
Imugene Limited has received a Notice of Allowance from the Chinese Patent Office for a patent protecting its CD19-expressing oncolytic virus, onCARlytics, in China, Asia’s largest market. This patent, which extends protection until 2038, covers the method of composition and use of onCARlytics, a virus that targets solid tumor cells by forcing them to express the CD19 protein. The patent’s approval is a strategic move to secure Imugene’s intellectual property in a major market, supporting its ongoing clinical trials and reinforcing its position in the immuno-oncology industry.
Imugene Limited has announced a change in the director’s interest, with Kim Drapkin acquiring 2,000,000 Restricted Stock Units (RSUs) without consideration. This issuance of RSUs, approved by shareholders, reflects the company’s commitment to align the interests of its leadership with stakeholders, potentially impacting its strategic direction and growth.
Imugene Limited has announced the issuance of unquoted equity securities, totaling 6,000,000 restricted stock units and 22,888,875 performance rights awards under their employee incentive scheme. This move is likely aimed at aligning employees’ interests with the company’s growth objectives, potentially enhancing operational focus and strengthening its market position.
Imugene Limited announced the quotation of 5,722,219 ordinary fully paid securities on the Australian Securities Exchange, following the exercise of options or conversion of convertible securities. This development signifies an expansion in the company’s capital resources, potentially enhancing its financial positioning and supporting its ongoing research and development efforts within the competitive biotech industry.
Imugene Limited announced promising results from its Phase 1b trial of azer-cel, a CD19 CAR T therapy, in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial showed a 57% complete response rate among evaluable patients, with two additional complete responses recently observed. The trial highlights azer-cel’s potential in addressing unmet needs in difficult-to-treat patient populations, especially those who have failed multiple lines of therapy, including autologous CAR T treatments. The company is actively enrolling patients across 13 US sites and up to 5 sites in Australia, with ongoing monitoring for response durability.